Acrivon Therapeutics (ACRV) Research & Development (2022 - 2026)
Acrivon Therapeutics (ACRV) posted Research & Development of $13.84 million for Q2 2026, down 14.4% from $16.18 million a year earlier and down 8.7% from the prior quarter.
Powered by 
Analysis
Acrivon Therapeutics (ACRV) Research & Development (2022 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Research & Development at Acrivon Therapeutics was $57.4 million, down 16.9% year-over-year; for FY2025, it came in at $59.99 million, down 6.3% from FY2024.
- Annual Research & Development shows a four-year compound annual growth rate of 81.7% (FY2021 to FY2025).
- In prior years, Acrivon Therapeutics' Research & Development was $63.99 million in FY2024 (+39.0%), $46.02 million in FY2023 (+92.2%), $23.95 million in FY2022 (+335.4%) and $5.5 million in FY2021.
- Quarterly Research & Development has run from a low of $9.76 million in Q1 2023 to a high of $18.86 million in Q3 2024 over five years.
- On a year-over-year basis, Research & Development has declined in each of the last four quarters, with growth averaging 10.2% over the last eight quarters.
- The strongest year-over-year quarter for Research & Development in the past five years was Q3 2024, with growth of 83.7%; the weakest was Q3 2025, with a decline of 27.7%.
- According to Business Quant data, Research & Development for the three prior quarters was $15.17 million (Q1 2026), $14.75 million (Q4 2025) and $13.65 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Acrivon Therapeutics | 88.27 Mn | 88.27 Mn | - | 13.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.84 Mn |
| Mar 31, 2026 | 15.17 Mn |
| Dec 31, 2025 | 14.75 Mn |
| Sep 30, 2025 | 13.65 Mn |
| Jun 30, 2025 | 16.18 Mn |
| Mar 31, 2025 | 15.41 Mn |
| Dec 31, 2024 | 18.63 Mn |
| Sep 30, 2024 | 18.86 Mn |
| Jun 30, 2024 | 15.03 Mn |
| Mar 31, 2024 | 11.47 Mn |
| Dec 31, 2023 | 15.48 Mn |
| Sep 30, 2023 | 10.27 Mn |
| Jun 30, 2023 | 10.52 Mn |
| Mar 31, 2023 | 9.76 Mn |
| Dec 31, 2022 | 18.45 Mn |
API Access
Acrivon Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ACRV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ACRV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ACRV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();